| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Poly(4-vinylphenol) does not have a specific pharmacological target as it is a polymer and endogenous metabolite rather than a therapeutic drug. As a polymer, it is used as a cross-linking agent and a sensitizer of titania for visible light photocatalysis. It can also be used as a water-resistant wood adhesive. Its "target" in research is material science applications.
|
|---|---|
| ln Vitro |
In vitro activity of Poly(4-vinylphenol) is not evaluated as a bioactive compound with pharmacological effects. Its utility lies in its material properties as a polymer cross-linking agent. It is used to prepare non-toxic films and as a sensitizer for photocatalysis. Its "activity" is reflected in its chemical properties as a polymer.
|
| ln Vivo |
In vivo, Poly(4-vinylphenol) is not administered as a therapeutic agent. It is an endogenous metabolite. Its primary applications are in material science, including the preparation of non-toxic films, photocatalysis, and as a wood adhesive. It is not a drug and has no therapeutic indications.
|
| Enzyme Assay |
In vitro enzyme assays with Poly(4-vinylphenol) are not typically performed as the compound is a polymer rather than a small molecule substrate for enzymes. Its utility lies in its material properties and applications in polymer chemistry. It is used as a cross-linking agent and in the preparation of films and coatings.
|
| Cell Assay |
Poly(4-vinylphenol) is not typically used in cell culture experiments as a bioactive compound for treating cells. However, it may be used in the preparation of non-toxic films for cell culture applications or as a coating material. Its primary use is in material science and polymer chemistry research.
|
| Animal Protocol |
In vivo animal experiments with Poly(4-vinylphenol) are not commonly performed as the compound is a polymer and endogenous metabolite rather than a therapeutic agent. If used, it would be in material science applications. Its primary significance is in research as a polymer for film preparation and photocatalysis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Poly(4-vinylphenol) are not relevant as it is a polymer and endogenous metabolite rather than a therapeutic agent. As a polymer, it is not administered as a drug. Its properties are characterized in material science applications. It has a density of 1.16 g/cm3 and a melting point of 170°C.
|
| Toxicity/Toxicokinetics |
Poly(4-vinylphenol) has a low toxicity profile as it can be used to prepare non-toxic films. It is an endogenous metabolite. For research use, standard laboratory safety practices are sufficient. It is not classified as a highly hazardous substance. Comprehensive toxicology studies have not been published for this compound.
|
| Additional Infomation |
Poly(4-vinylphenol) (PVP, Poly(4-hydroxystyrene)) is a polymer cross-linking agent that can be used to prepare non-toxic films. It is a sensitizer of titania for visible light photocatalysis and can also be used as a water-resistant wood adhesive. It is an endogenous metabolite. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only.
|
| Molecular Formula |
(C8H8O)X
|
|---|---|
| Molecular Weight |
120.14852
|
| Exact Mass |
120.058
|
| CAS # |
24979-70-2
|
| Appearance |
White to off-white solid powder
|
| Density |
1.16 g/mL at 25ºC(lit.)
|
| Boiling Point |
206.2ºC at 760 mmHg
|
| Melting Point |
360ºC (dec.)
|
| Flash Point |
308ºC
|
| Vapour Pressure |
0.168mmHg at 25°C
|
| Index of Refraction |
n20/D 1.6
|
| LogP |
2.035
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.3229 mL | 41.6146 mL | 83.2293 mL | |
| 5 mM | 1.6646 mL | 8.3229 mL | 16.6459 mL | |
| 10 mM | 0.8323 mL | 4.1615 mL | 8.3229 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
